Long-term effectiveness, safety and prognostic factors of response to treatment with bimekizumab in patients with plaque psoriasis: results from a real-world multicentre study

In this multicentre observational retrospective study, bimekizumab demonstrated high effectiveness, together with a good safety profile, over a period of 78 weeks. The presence of psoriatic arthritis, obesity and longer disease duration seemed to influence response to treatment negatively in the mid term (24 weeks), while previous biologic exposure affected clinical outcomes in the long term (52 weeks).